Tsai Capital Corp Buys 3,016 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Tsai Capital Corp boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,797 shares of the company’s stock after purchasing an additional 3,016 shares during the period. IDEXX Laboratories comprises approximately 2.6% of Tsai Capital Corp’s portfolio, making the stock its 12th biggest holding. Tsai Capital Corp’s holdings in IDEXX Laboratories were worth $3,637,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allstate Corp bought a new position in shares of IDEXX Laboratories during the 4th quarter worth $1,009,000. DnB Asset Management AS grew its stake in IDEXX Laboratories by 1.8% in the 4th quarter. DnB Asset Management AS now owns 14,675 shares of the company’s stock valued at $6,067,000 after buying an additional 254 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of IDEXX Laboratories by 23.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 442,484 shares of the company’s stock worth $182,941,000 after acquiring an additional 83,964 shares in the last quarter. Norges Bank bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $412,258,000. Finally, Caisse Des Depots ET Consignations bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $637,000. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $415.87 on Friday. The stock’s 50-day moving average is $437.07 and its 200 day moving average is $443.27. The stock has a market cap of $33.71 billion, a price-to-earnings ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.